×

Procedure Enabled by Innovative Cardica Technology to be Featured at STS/AATS Tech-Con 2016

REDWOOD CITY, Calif., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Cardica, Inc. (Nasdaq:CRDC) today announced the company’s MicroCutter XCHANGE® 30 surgical stapler, with a shaft diameter of 5 millimeters and the capability to articulate 80 degrees, will be featured in a presentation describing a cutting-edge lobectomy technique at The Society of Thoracic Surgeons and American Association for Thoracic Surgery’s Tech Conference (Tech-Con) to be held January 23-24 in Phoenix, Ariz.

Tech-Con focuses on cutting-edge devices and procedures that have not yet been widely adopted by cardiothoracic surgeons.

A “Lung Surgery of the Future” presentation by Joel Dunning, M.D., cardiothoracic surgeon at James Cook University Hospital, Department of Cardiothoracic Surgery in Middlesbrough, U.K., will describe Microlobectomy, the less-invasive technique Dr. Dunning pioneered for video-assisted lung surgery, or VATS, which is enabled by Cardica’s MicroCutter XCHANGE 30.

Dr. Dunning’s presentation, titled, “Microlobectomy: A Novel Form of Video-Assisted Thoracoscopic Lobectomy,” is scheduled at 2:05 p.m. MST, Saturday January 23, in room 120D in the Phoenix Convention Center.

About the MicroCutter XCHANGE 30
The MicroCutter XCHANGE 30, the world’s first and only five-millimeter surgical stapler that articulates to 80 degrees, is a cartridge-based minimally invasive surgical stapling system. The device’s small size and articulation range is designed to enhance the surgeon’s access and visualization at the surgical site, and to mitigate limitations on the advancement of minimally invasive surgical approaches created by larger stapling devices. As the smallest-profile articulating stapler available today, the MicroCutter XCHANGE 30 may reduce the amount of dissection and tissue handling required to position the stapler in confined spaces, enabling access to difficult-to-reach anatomy.

About Cardica
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and minimally invasive surgical procedures. Cardica's technology portfolio is intended to reduce operating time and facilitate minimally invasive and robot-assisted surgeries. Cardica’s MicroCutter XCHANGE® 30, that includes a cartridge-based articulating surgical stapling device with a five-millimeter shaft diameter and staples, is manufactured and cleared for use in the United States for transection and resection in multiple open or minimally invasive urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the small and large intestine and the transection of the appendix. The MicroCutter XCHANGE 30 White Cartridge staple has application in vascular tissue. In addition, Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 56,500 units throughout the world.

Forward-Looking Statements
The statements in this press release regarding Cardica’s beliefs as to the benefits expected to be obtained from the use of the MicroCutter XCHANGE® 30, are "forward-looking statements." There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including: that Cardica may not be successful in its efforts to complete the development of its combination device (designed to use two different size cartridges) or achieve optimization of Cardica’s supply chain for its combination device; that Cardica may not receive regulatory approval for indications not currently approved; as well as other risks detailed from time to time in Cardica’s reports filed with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, under the caption “Risk Factors,” filed on November 12, 2015. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica’s reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.


Contact: Bob Newell Vice President, Finance and Chief Financial Officer (650) 331-7133 investors@cardica.com

Source:Cardica, Inc.